查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1539573

血漿分餾市場規模、佔有率和成長分析：按產品、按應用、按最終用戶、按地區 - 行業預測，2024-2031 年

Plasma Fractionation Market Size, Share, Growth Analysis, By Product (Albumin, Immunoglobulins), By Application (Neurology, Oncology), By End Use (Hospitals & Clinics, Clinical Research), By Region - Industry Forecast 2024-2031
出版日期: | 出版商: SkyQuest | 英文 219 Pages | 商品交期: 3-5個工作天內

價格
簡介目錄

2022年全球血漿分餾市場規模約為308.7億美元，將從2023年的334.3億美元增至2031年的632.7億美元，預計在預測期內（2024-2031年）將以複合年成長率成長。 %。

在 COVID-19 大流行期間，對恢復期血漿的需求激增，因為恢復期血漿最初用於治療感染病毒的患者。根據 Frontiers 2021 年 6 月的一篇論文，國際上廣泛使用恢復期血漿來管理 COVID-19 病例並減緩疾病進展。研究表明，恢復期血漿輸注有助於症狀改善和病毒清除，增加了血漿分餾的需要。然而，隨著疫情消退和感染率下降，預計康復期血漿市場將在預測期內穩定成長。有幾個因素促進了血漿分餾市場的擴張。其中包括免疫球蛋白在各個治療領域的使用增加、老年人口的增加以及全世界血漿採集設施的增加。根據世界衛生組織2022年10月的資料，到2050年，全球60歲以上老年人口預計將增加近兩倍，其中大部分集中在低收入和中等收入國家。這種人口結構的變化預計將增加罕見疾病的盛行率，從而增加對血漿產品的需求。此外，馮·維勒布蘭德病的流行影響了世界上約 1% 的人口，這進一步增加了對血漿衍生治療的需求。 Bio Products Laboratory Ltd 和 Freedom Plasma 等開設的血漿採集中心的擴建預計將透過促進血漿產品生產來支持市場成長。此外，領先企業的產品創新和策略聯盟等努力正在推動產業成長。然而，嚴格的監管要求、高成本和報銷問題等挑戰可能會影響市場動態。

目錄

介紹

  • 研究目的
  • 定義
  • 市場範圍

調查方法

  • 資訊採購
  • 二手資料來源和主要資料來源
  • 市場規模預測
  • 市場假設與限制

執行摘要

  • 市場概況展望
  • 供需趨勢分析
  • 按細分市場的機會分析

市場動態及展望

  • 市場動態
    • 促進因素
    • 機會
    • 抑制因素
    • 任務
  • 波特的分析

主要市場考察

  • 市場成功因素
  • 競爭程度
  • 主要投資機會
  • 市場魅力指數
  • 生態系繪圖
  • 技術分析
  • 成本分析
  • 市場趨勢分析
  • 競品分析
  • 供應鏈分析
  • 投資分析
  • 專利分析
  • 價值鏈分析
  • 管轄權分析
  • 貿易分析
  • 案例研究分析
  • 波特五力分析

血漿分餾市場：依產品

  • 免疫球蛋白
    • 靜脈注射免疫球蛋白
    • 皮下注射免疫球蛋白
    • 其他
  • 濃縮凝血因子
    • 因子VIII
    • 因子IX
    • 血管性血友病因子
    • 凝血酶原複合物濃縮物
    • 纖維蛋白原濃縮物
    • 因子XIII
    • 其他
      • 白蛋白
      • 蛋白酶抑制劑
      • 其他

血漿分餾市場：依應用分類

  • 神經病學
  • 免疫學
  • 血液學
  • 重症監護
  • 呼吸系統醫療設備
  • 血液腫瘤學
  • 風濕病學
  • 其他

血漿分餾市場：依最終用戶分類

  • 醫院/診所
  • 臨床研究實驗室
  • 學術機構

血漿分餾市場規模：依地區分類

  • 市場概況
  • 北美洲
    • 美國
    • 加拿大
  • 歐洲
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 其他歐洲國家地區
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 其他亞太地區
  • 拉丁美洲
    • 巴西
    • 其他拉丁美洲地區
  • 中東和非洲 (MEA)
    • 海灣合作理事會國家
    • 南非
    • 其他中東/非洲地區

競爭格局

  • 前5名企業對比
  • 主要企業市場定位（2023年）
  • 主要市場參與者所採取的策略
  • 近期市集活動
  • 主要企業市場佔有率（2023年）

主要企業簡介

  • CSL Behring（Australia）
  • Grifols（Spain）
  • Octapharma（Switzerland）
  • Kedrion（Italy）
  • China Biologic Products Holdings（China）
  • Sanquin（Netherlands）
  • Bio Products Laboratory（UK）
  • Japan Blood Products Organization（Japan）
  • LFB Group（France）
  • Shanghai RAAS Blood Products（China）
  • Green Cross Corporation（South Korea）
  • Baxter International Inc.（US）
  • Takeda Pharmaceutical Company Limited（Japan）
  • Beijing Tiantan Biological Products（China）
  • Biotest AG（Germany）
  • China National Pharmaceutical Group Co.（Sinopharm）（China）
  • GC Pharma（South Korea）
  • ADMA Biologics（US）
  • Emergent BioSolutions（US）
  • Renishaw plc（UK）
  • HP Inc.（USA）
簡介目錄
Product Code: SQMIG35H2165

Global Plasma Fractionation Market size was valued at around USD 30.87 billion in 2022 and is expected to rise from USD 33.43 billion in 2023 to reach a value of USD 63.27 billion by 2031, at a CAGR of 8.3% over the forecast period (2024-2031).

During the COVID-19 pandemic, the demand for convalescent plasma surged as it was initially used to treat patients infected with the virus. According to a June 2021 Frontiers paper, convalescent plasma was widely administered internationally to manage COVID-19 cases and mitigate disease progression. Studies have shown that convalescent plasma transfusions contributed to improved symptoms and virus clearance, leading to a heightened need for plasma fractions. However, as the pandemic has waned and infection rates have decreased, the market for convalescent plasma is expected to experience steady growth throughout the forecast period. Several factors are contributing to the expansion of the plasma fractionation market. These include the increasing use of immunoglobulins in various therapeutic areas, a growing elderly population, and a rise in plasma collection facilities worldwide. According to WHO data from October 2022, the global population aged over 60 is projected to nearly triple by 2050, with a significant concentration in low- and middle-income countries. This demographic shift is anticipated to increase the prevalence of rare diseases and, consequently, the demand for plasma products. Additionally, the prevalence of Von Willebrand's disease, affecting approximately 1% of the global population, further drives the need for plasma-derived treatments. The expansion of plasma collection centers, such as those opened by Bio Products Laboratory Ltd and Freedom Plasma, is expected to support market growth by boosting plasma-based product production. Furthermore, industry growth is bolstered by major players' initiatives, including product innovations and strategic partnerships. However, challenges such as stringent regulatory requirements, high costs, and reimbursement issues may impact market dynamics.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Plasma Fractionation market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Plasma Fractionation Market Segmental Analysis

The global plasma fractionation market is segmented based on product, method, application, end use, and region. Based on product, the market is segmented into Albumin, Immunoglobulins (Intravenous, Subcutaneous, Others), Coagulation Factors (Factor VIII, Factor XI, Von Willebrand, Prothrombin complex, Fibrinogin, factor XIII, others), Protease Inhibitors, Others. By application, the market is segmented into Neurology, Hematology, Oncology, Immunology, Critical care, Hemato-Oncology, rheumatology, Pulmonology and others. By end use, the market is segmented into hospitals & clinics, clinical research, and others. Based on region, the market is segmented into North America, Europe, Asia-Pacific, South America, and MEA.

Drivers of the Global Plasma Fractionation Market

In recent years, protease inhibitors such as alpha-1-antitrypsin (AAT) have gained prominence in treating hepatic and lung conditions like cirrhosis, fibrosis, and liver inflammation. Alpha-1-antitrypsin deficiency (AATD) is a hereditary metabolic disorder that often goes undiagnosed and can lead to severe health issues. In the US, AATD accounts for 2-3% of emphysema cases. This condition leads to early-onset pan-lobular emphysema in both smokers and non-smokers, while the abnormal accumulation of alpha-1-antitrypsin in the liver causes various liver diseases. Although AATD occurs globally, its prevalence differs by region. Chronic obstructive pulmonary disease (COPD), which includes emphysema and chronic bronchitis, is frequently associated with severe AATD. According to a study published by Elsevier B.V. in July 2023, the prevalence of the PI*ZZ Alpha-1 Antitrypsin genotype among COPD patients varies significantly by region: approximately 50% in Europe, 37% in America, 9% in Asia, 3% in Australasia, and 1% in Africa. The estimated prevalence of COPD among individuals over 40 years old is 13.51% in the US, 12.45% in Europe, 13.22% in Africa, 11.70% in Asia, and 11.86% in Australasia. This data highlights a markedly higher prevalence in Europe, the US, Canada, New Zealand, and Australia compared to lower rates observed in parts of Asia and Africa.

Restraints in the Global Plasma Fractionation Market

Recent approvals for recombinant factors such as AFSTYLA (CSL), VONVENDI (Takeda/Shire), and Kovaltry (Bayer) are expected to boost financial performance for companies in this market segment. Recombinant factor products are categorized into two types: standard half-life and extended half-life products. Standard half-life products remain in the body for the same duration as natural factor VIII or IX, while extended half-life products are engineered to last longer in the body compared to conventional versions. According to the World Federation of Hemophilia's 2020 Annual Global Survey, recombinant factors VIII and IX are increasingly preferred in developed countries over plasma-derived alternatives for treating bleeding disorders. Meanwhile, their adoption is also rising in emerging markets such as Brazil, India, and Russia. This growing preference for recombinant factors is likely to restrict the development of plasma-derived coagulation factors, potentially affecting overall market growth.

Market Trends of the Global Plasma Fractionation Market

Immunoglobulins are the primary treatment for various immunologic, hematologic, and neurologic disorders. Advances in technology over the past decade have led to an increase in the diagnosis of immunological conditions, driving up the clinical need for immunoglobulins as more patients are identified with immunodeficiency. The growing body of genetic research aimed at defining and diagnosing these conditions further contributes to the demand for immunoglobulins. According to IG Living, a publication for the immunoglobulin (IG) community, about 20-60% of immunoglobulin use is for off-label indications, with these uses having recently surpassed those for on-label indications. The rise in rare and autoimmune disorders, coupled with an increase in global immunology research, is accelerating market growth. The National Center for Advancing Translational Sciences reported in February 2022 that only a fraction of the 7,000 to 10,000 rare diseases have available treatments. As the number of rare disorders rises, so does the demand for immunoglobulins, further fueling market expansion.

Table of Contents

Introduction

  • Objectives of the Study
  • Definitions
  • Market Scope

Research Methodology

  • Information Procurement
  • Secondary & Primary Data Sources
  • Market Size Estimation
  • Market Assumptions & Limitations

Executive Summary

  • Market Overview Outlook
  • Supply Demand Trend Analysis
  • Segmental Opportunity Analysis

Market Dynamics & Outlook

  • Market Dynamics
    • Drivers
    • Opportunities
    • Restraints
    • Challenges
  • Porters Analysis
    • Competitive rivalry
    • Threat of Substitute Products
    • Bargaining Power of Buyers
    • Threat of New Entrants
    • Bargaining Power of Suppliers

Key Market Insights

  • Key Success Factors of The Market
  • Degree Of Competition
  • Top Investment Pockets
  • Market Attractive Index
  • Ecosystem Mapping
  • Technology Analysis
  • Cost Analysis
  • Market Trend Analysis
  • Competition Analysis
  • Supply chain analysis
  • Investment Analysis
  • Patent analysis
  • Value chain analysis
  • Jurisdiction analysis
  • Trade analysis
  • Case study analysis
  • Porter's five forces analysis

Plasma Fractionation Market by product

  • Immunoglobulins
    • Intravenous Immunoglobulins
    • Subcutaneous Immunoglobulins
    • Other Immunoglobulins
  • Coagulation Factor Concentrates
    • Factor VIII
    • Factor IX
    • Von Willebrand Factor
    • Prothrombin Complex Concentrate
    • Fibrinogen Concentrates
    • Factor XIII
    • Other Coagulation Factor Concentrates
      • Albumin
      • Protease Inhibitors
      • Other Plasma Products

Plasma Fractionation Market by application

  • Neurology
  • Immunology
  • Hematology
  • Critical care
  • Pulmonology
  • Hemato-Oncology
  • Rheumatology
  • Other Applications

Plasma Fractionation Market by end-user

  • Hospitals and Clinics
  • Clinical Research Laboratories
  • Academic institutes

Plasma Fractionation Market Size by Region

  • Market Overview
  • North America
    • USA
    • Canada
  • Europe
    • Germany
    • UK
    • France
    • Italy
    • Spain
    • Rest of Europe
  • Asia Pacific
    • China
    • India
    • Japan
    • South Korea
    • Rest of Asia-Pacific
  • Latin America
    • Brazil
    • Rest of Latin America
  • Middle East & Africa (MEA)
    • GCC Countries
    • South Africa
    • Rest of MEA

Competitive Landscape

  • Top 5 Player Comparison
  • Market Positioning of Key Players, 2023
  • Strategies Adopted by Key Market Players
  • Recent Activities in the Market
  • Key Companies Market Share (%), 2023

Key Company Profiles

  • CSL Behring (Australia)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Grifols (Spain)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Octapharma (Switzerland)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Kedrion (Italy)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • China Biologic Products Holdings (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Sanquin (Netherlands)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Bio Products Laboratory (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Japan Blood Products Organization (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • LFB Group (France)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Shanghai RAAS Blood Products (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Green Cross Corporation (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Baxter International Inc. (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Takeda Pharmaceutical Company Limited (Japan)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Beijing Tiantan Biological Products (China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Biotest AG (Germany)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • China National Pharmaceutical Group Co. (Sinopharm)(China)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • GC Pharma (South Korea)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • ADMA Biologics (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Emergent BioSolutions (US)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • Renishaw plc (UK)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments
  • HP Inc. (USA)
    • Company Overview
    • Business Segment Overview
    • Financial Updates
    • Key Developments